evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,337 questions · 1,354 findings · 566 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 307 · 22.7%GRADE not reported 81 · 6%Very low 424 · 31.3%Low 310 · 22.9%Moderate 189 · 14%High 43 · 3.2%

PERPHENAZINE vs placebo

Adverse events: serious adverse events ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Mometasone/formoterol (MF/F) vs placebo

Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).

1 finding from 1 review

Mometasone/formoterol (MF/F) vs placebo

Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).

1 finding from 1 review

First‐line thiazides vs calcium channel blockers

Total serious adverse events Duration: 1.75 to 3 years · patients with hypertension

First‐line thiazides showed no clear difference in total serious adverse events Duration: 1.75 to 3 years compared with first‐line calcium channel blockers (low certainty).

1 finding from 1 review

Ocrelizumab vs placebo

Number of participants with any serious adverse events · primary progressive multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Ocrelizumab vs interferon beta‐1a

Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Cediranib plus chemotherapy vs placebo plus chemotherapy

Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).

1 finding from 1 review

Bevacizumab plus chemotherapy vs chemotherapy alone

Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer

Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).

1 finding from 1 review

Human recombinant activated protein C vs placebo

Serious adverse events (adult and paediatric patients) · patients with severe sepsis or septic shock

Human recombinant activated protein C showed no clear difference in serious adverse events (adult and paediatric patients) compared with placebo (moderate certainty).

1 finding from 1 review

Music therapy vs placebo or usual care

Adverse events Any serious or non‐serious adverse event · Individuals with autism spectrum disorder

Music therapy showed no clear difference in adverse events Any serious or non‐serious adverse event compared with placebo therapy or standard care (moderate certainty).

1 finding from 1 review

Short‐stay unit hospitalisation vs usual care

Serious adverse events at time point closest to 90 days · participants with internal medicine diseases and conditions

It is very uncertain whether short‐stay unit hospitalisation changes serious adverse events at time point closest to 90 days compared with usual care (very low certainty).

1 finding from 1 review